Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

Cory Renauer, The Motley Fool
·2 min read
Analyst Downgrades AstraZeneca Stock Due to Vaccine Side Effect Concerns

The odds of experiencing a fatal blood clot following inoculation with AstraZeneca's COVID-19 vaccine are less than one in a million, but that was enough to spook Argus Research.